Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 8/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.79 |
| ▸ | THRB | P10828 | 7/20 | 0.79 |
| ▸ | BLM | P54132 | 7/20 | 0.79 |
| ▸ | RECQL | P46063 | 6/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.79 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.79 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.79 |
| ▸ | TOP2A | P11388 | 5/20 | 0.79 |
| ▸ | BRCA1 | P38398 | 5/20 | 0.79 |
| ▸ | MAPT | P10636 | 5/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.79 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.79 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.79 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.79 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.79 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.79 |
| ▸ | STAT6 | P42226 | 3/20 | 0.79 |
| ▸ | HTT | P42858 | 3/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL43830 | 0.97 | MEN1 (0.83) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL399353 | 0.97 | MEN1 (0.75) | MEN1KMT2ATHRBBLMRECQL | |
| Hydrochloric Acid SCHEMBL27900762 | 0.97 | MEN1 (0.83) | MEN1KMT2ATHRBBLMRECQL | |
| Hydrochloric Acid SCHEMBL1771543 | 0.97 | MEN1 (0.83) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL248564 | 0.95 | S100A4 (0.85) | MEN1KMT2ATHRBBLMRECQL | |
| Hydrochloric Acid SCHEMBL28160744 | 0.95 | S100A4 (0.84) | MEN1KMT2ATHRBBLMRECQL | |
| Hydrochloric Acid SCHEMBL331063 | 0.95 | S100A4 (0.84) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL22409662 | 0.94 | MEN1 (0.80) | MEN1KMT2ATHRBBLMRECQL | |
| Doxorubicin SCHEMBL27834123 | 0.94 | MEN1 (0.91) | MEN1KMT2ATHRBBLMRECQL | |
| SCHEMBL29048581 | 0.93 | MEN1 (0.79) | MEN1KMT2ATHRBBLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112930346-A | Novel compounds as NADPH oxidase inhibitors | 金其尤泰克斯瑞士股份有限公司 | 2021-06-08 | — | — | CN | claimed |
| US-20120059240-A1 | METHOD FOR PREPARATION OF MICELLAR HYBRID NANOPARTICLES FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS AND COMPOSITIONS THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-03-08 | — | — | US | claimed |
| WO-2023121753-A1 | BIOMOLECULE-POLYMER-PHARMACEUTICAL AGENT CONJUGATES FOR DELIVERING THE PHARMACEUTICAL AGENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2023-06-29 | — | — | WO | disclosed |
| CN-115944729-A | Thermotherapy composition, medicine composition, preparation method and application thereof | 中国药科大学 | 2023-04-11 | — | — | CN | disclosed |
| CN-107072944-B | Liposomal ciprofloxacin formulations with anti-nontuberculous mycobacterial activity | 阿拉迪姆公司 | 2021-11-02 | — | — | CN | disclosed |
| CN-104884091-B | Minimally toxic prodrugs | 科比欧尔斯公司 | 2021-07-20 | — | — | CN | disclosed |
| CN-109715195-A | Drug combination for converting neoplastic cells into non-neoplastic cells and use thereof | 伊斯迪德股份公司 | 2019-05-03 | — | — | CN | disclosed |
| WO-2017046037-A1 | NANOPARTICLES LOADED WITH ACTIVE INGREDIENTS, THEIR PROCESS OF PREPARATION AND THEIR USES | ONXEO (FR) | 2017-03-23 | — | — | WO | disclosed |
| US-20170071866-A1 | NANOPARTICLES LOADED WITH ACTIVE INGREDIENTS, THEIR PROCESS OF PREPARATION, AND THEIR USES | ONXEO S.A. (FR) | 2017-03-16 | — | — | US | disclosed |
| CN-106456551-A | Liposomes that form drug nanocrystals after freeze-thaw | 阿拉迪姆公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-103845361-B | Graphene quantum dot purposes in preparing oncotherapy sensitizer | 国家纳米科学中心 | 2016-07-06 | — | — | CN | disclosed |
| US-5817321-A | ANTICANCER CHEMOTHERAPUTIC AGENT, POLYETHER BLOCK COPOLYMER | SUPRATEK PHARMA, INC. (CA) | 1998-10-06 | — | — | US | disclosed |
| US-5817625-A | REDICING THE SIDE EFFECTS OF RADIATION TREATMENT AND CHEMOTHERAPY, PEDIATRICS | ONCOGENE SCIENCE, INC. (US) | 1998-10-06 | — | — | US | disclosed |
| WO-1998039458-A1 | PROCESS FOR PREPARING DOXORUBICIN | PHARMACIA & UPJOHN S.P.A. (IT) | 1998-09-11 | — | — | WO | disclosed |
| US-5635489-A | Methods of prevention of oral mucositis with transforming growth factor β | ONCOGENE SCIENCE, INC. (US) | 1997-06-03 | — | — | US | disclosed |
| EP-0678031-A4 | TISSUE-DERIVED TUMOR GROWTH INHIBITORS, METHODS OF PREPARATION AND USES THEREOF. | ONCOGENE SCIENCE INC (US) | 1996-07-17 | — | — | EP | disclosed |
| EP-0678031-A1 | TISSUE-DERIVED TUMOR GROWTH INHIBITORS, METHODS OF PREPARATION AND USES THEREOF | Oncogene Science, Inc. (US) | 1995-10-25 | — | — | EP | disclosed |
| WO-1994006459-A9 | TISSUE-DERIVED TUMOR GROWTH INHIBITORS, METHODS OF PREPARATION AND USES THEREOF | — | 1994-05-26 | — | — | WO | disclosed |
| WO-1994006459-A1 | TISSUE-DERIVED TUMOR GROWTH INHIBITORS, METHODS OF PREPARATION AND USES THEREOF | ONCOGENE SCIENCE, INC. (US) | 1994-03-31 | — | — | WO | disclosed |
| US-4215062-A | Anthracycline synthesis | UNIVERSITY OF KANSAS ENDOWMENT ASSOCIATION (US) | 1980-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170071866-A1 | NANOPARTICLES LOADED WITH ACTIVE INGREDIENTS, THEIR PROCESS OF PREPARATION, AND THEIR USES | MPO, EXOSC9, CD63 | MEN1 3260/4885KMT2A 3969/4885THRB 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.